Vienna-based research institute specializing in pediatric cancer biology, precision oncology, and genomic diagnostics for childhood tumours and rare diseases.
St. Anna Children's Cancer Research Institute (Kinderkrebsforschung) is a Vienna-based research centre dedicated to understanding and treating childhood cancers, with deep specialization in pediatric oncology and rare diseases. They develop preclinical models (patient-derived xenografts, organoids), apply genomic and bioinformatic approaches to identify actionable drug targets in pediatric tumours, and work on personalizing diagnosis and treatment for children with cancer and immune disorders. Their work spans from basic molecular research on leukemia and solid tumours through to clinical translation, including digital survivorship tools and standardized next-generation sequencing workflows for precision medicine.
Core focus across ChiLTERN, ITCC-P4, CLOSER, VAGABOND, PRIMAGE, TREL, PanCareSurPass, and Instand-NGS4P — covering liver tumours, leukemia, neuroblastoma, and solid tumours in children.
ITCC-P4 builds PDX/GEMM/organoid platforms for pediatric cancers; VAGABOND validates target-drug combinations; PRIMAGE develops in-silico predictive models for neuroblastoma and DIPG.
Instand-NGS4P standardizes NGS workflows with pharmacogenetics and gene panels; FIND-seq interrogates non-coding DNA in leukemia; iDysChart maps immune dysregulation at the molecular level.
EJP RD focuses on rare disease data sharing and FAIR principles; iDysChart (coordinated by St. Anna) charts inborn errors of immunity; ERICA coordinates rare disease research networks.
PanCareSurPass implements a digital Survivorship Passport integrated with electronic health records; Instand-NGS4P includes e-reporting and e-medication standards.
CLOSER bridges South American and European childhood leukemia research; TREL twins Lithuanian institutions to improve solid tumour survival rates through training and knowledge transfer.
In their earlier H2020 period (2016–2019), St. Anna focused heavily on building preclinical tumour models — PDX, organoids, and in-silico modelling for neuroblastoma and brain tumours — along with foundational translational research in childhood leukemia. From 2020 onward, their focus shifted toward genomics-driven precision medicine: standardized NGS workflows, pharmacogenetics, non-coding DNA analysis, and digital tools for survivorship care and quality assurance (EQA standards). This evolution reflects a clear trajectory from disease modelling toward clinical-grade molecular diagnostics and personalized treatment.
St. Anna is moving from laboratory tumour models toward standardized genomic diagnostics and digital health integration, making them an increasingly valuable partner for precision medicine and clinical implementation projects.
St. Anna operates primarily as an active partner in large European consortia (10 of 12 projects), contributing specialized pediatric cancer expertise to multi-country networks. They coordinate selectively — their two coordinated projects (iDysChart ERC grant, FIND-seq ERC grant) are both investigator-driven ERC grants rather than large consortium-led efforts, suggesting they lead where deep scientific autonomy is needed. With 248 unique partners across 38 countries, they function as a well-connected specialist node in the European pediatric oncology research landscape rather than a consortium-building hub.
St. Anna has collaborated with 248 distinct partners across 38 countries, indicating a deeply international network that extends well beyond Europe — CLOSER, for example, bridges South American and European institutions. Their partnerships are concentrated in clinical and translational cancer research networks.
St. Anna occupies a rare niche as a research institute exclusively focused on childhood cancer — most oncology centres treat adult cancers with pediatric as a sideline. Their combination of preclinical modelling capabilities (organoids, PDX, GEMM), genomics expertise (NGS, pharmacogenetics), and rare disease knowledge in a single pediatric-focused institution makes them a distinctive partner. For consortium builders, they bring something hard to find elsewhere: deep pediatric oncology specialization paired with the infrastructure to move from molecular discovery to clinical-grade diagnostics.
